SCHEMBL1439591

SCHEMBL1439591

CC(C)(C)OC(=O)N1CCN(c2ccccc2C2COC(=O)N2)CC1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.44
BACE1 P56817 3/20 0.44
SMARCA2 P51531 1/20 0.41
SMARCA4 P51532 1/20 0.41
PBRM1 Q86U86 1/20 0.41
CKS1B P61024 1/20 0.41
SKP1 P63208 1/20 0.41
SKP2 Q13309 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
NAMPT P43490 1/20 0.41
TP53 P04637 2/20 0.40
THRB P10828 1/20 0.40
KIT P10721 1/20 0.40
TERT O14746 1/20 0.40
RET P07949 1/20 0.39
DTYMK P23919 1/20 0.39
PDK2 Q15119 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28907801 0.78 GPR119 (0.48) GPR119BACE1SMARCA2SMARCA4PBRM1
SCHEMBL12676368 0.77 GPR119 (0.49) GPR119BACE1SMARCA2SMARCA4PBRM1
SCHEMBL4851108 0.75 GPR119 (0.52) GPR119SMARCA2SMARCA4PBRM1CKS1B
SCHEMBL4258536 0.74 GPR119 (0.49) GPR119BACE1SMARCA2SMARCA4PBRM1
SCHEMBL114482 0.74 GPR119 (0.53) GPR119BACE1SMARCA2SMARCA4PBRM1
SCHEMBL17276765 0.73 CKS1B (0.55) GPR119SMARCA2SMARCA4PBRM1CKS1B
SCHEMBL28742235 0.73 GPR119 (0.52) GPR119BACE1SMARCA2SMARCA4PBRM1
SCHEMBL17276500 0.72 SMN1; SMN2 (0.62) GPR119SMARCA2SMARCA4PBRM1CKS1B
SCHEMBL4253782 0.72 GPR119 (0.46) GPR119BACE1SMARCA2SMARCA4PBRM1
SCHEMBL2382922 0.72 GAA (0.69) GPR119SMARCA2SMARCA4PBRM1CKS1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8865726-B2 Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors ARRAY BIOPHARMA INC. (US) 2014-10-21 US disclosed
US-20120178715-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS ARRAY BIOPHARMA INC. (US) 2012-07-12 US disclosed
WO-2011029027-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178715-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS MTOR, RICTOR, EIF4EBP1 GPR119 1785/4885BACE1 3672/4885SMARCA2 2341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.